Gene Transfer in the Cardiovascular System

Experimental Approaches and Therapeutic Implications

  • Keith L. March

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 189)

Table of contents

  1. Front Matter
    Pages i-xx
  2. Vectors and Gene Transfer Systems: Molecular Aspects of Delivery

    1. Front Matter
      Pages 1-1
    2. J. F. Dedieu, E. Vigne, C. Orsini, P. Denefle, M. Perricaudet, P. Yeh
      Pages 25-55
    3. Terence R. Flotte, Sandra A. Afione, Barry J. Byrne, B. Helen
      Pages 57-83
    4. Linda B. Jacobsen
      Pages 85-110
  3. Methods for Localizing Gene Transfer: Mechanical Aspects of Delivery

    1. Front Matter
      Pages 177-177
    2. Robert L. Wilensky
      Pages 179-199
    3. Robert W. Schroff, Lawrence L. Kunz
      Pages 219-236
  4. Gene Delivery for Local Vascular Expression

    1. Front Matter
      Pages 237-237
    2. James Burke, John Ojeifo, James A. Zwiebel
      Pages 255-278
    3. Robert S. Schwartz, Aloysius Chu, Myung Ho Jeong, Michael E. Staab, Sanjay S. Srivatsa, Vincent J. Pompili et al.
      Pages 293-306
    4. Jeffrey M. Isner
      Pages 307-330
  5. Gene Delivery for Local Cardiac Expression

    1. Front Matter
      Pages 331-331
    2. Mark H. Soonpaa, Loren J. Field
      Pages 333-353

About this book

Introduction

The goal of gene transfer is protein expression. a process brought about by the insertion of a gene coding for a foreign protein into target cells resulting in the synthesis of the foreign protein For gene therapy, a tmnsferred therapeutic gene must be expressed at a level beneficial for the patient. This chapter provides an introductory overview of the rapidly evolving field of non-viral approaches for gene delivery to rnarnrnalian cells. Although currently there are fewer ongoing clinical trials using non-viral approaches than those using viral based systems, the number of non-viral trials is increasing. The long range goal of some research groups is the development of a genetically engineered artificial virus targeted to specific cells in the human body. An arurual conference, organized by Cambridge Healthtech Institute entitled "Artificial Self-Assembling Systems for Gene Transfer", brings together researchers interested in this field [1]. Assembly of an artificial virus is very complex; other research groups aim to develop simpler delivery systems consisting of a plasmid combined with delivery agents. Viral-based systems are very successful for gene delivery, but despite their successes, viral-based systems have some geneml limitations and system-specific limitations. When employing a viml-based system, the following limitations should be considered: • size limitation of the inserted gene due to packaging constraints (e. g. adenovirus, retrovirus) . • potential tumorigenesis (e. g. retrovirus) • potential for insertional mutagenesis (greater than plasmid based systems) • potential imrnunogenicity (e. g.

Keywords

DNA cardiovascular gene therapy gene transfer genes

Editors and affiliations

  • Keith L. March
    • 1
    • 2
  1. 1.Krannert Institute of CardiologyIndiana University Medical CenterIndianapolisUSA
  2. 2.R. L. Roudebush VA Medical CenterIndianapolisUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-6277-1
  • Copyright Information Kluwer Academic Publishers 1997
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-7881-5
  • Online ISBN 978-1-4615-6277-1
  • Series Print ISSN 0166-9842
  • About this book